Bringing the fundamentals into focus…
Back to NeoGenomics, Inc.
How NeoGenomics, Inc. stacks up
NEO · against 387 other Healthcare companies of similar size
Overall
36/ 100
Near the bottom of its peers.
Ranked #307 of 388 · scores higher than 20% of peers
Bars: peers in each 10-point band of the overall score53 peers with an overall score of 30–39, including NEO · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around NEO| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | 100 | 0 / 2 | ||
| 2 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 2 | 15.6B DKK (≈$2.3B) | 96 | 96 | 99 | 96 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 2.29T KRW (≈$1.6B) | 88 | 83 | 90 | 96 | 0 / 2 | |
| 307 | 11.6B HKD (≈$1.5B) | 36 | 49 | 35 | 2 / 2 | ||
| 307 | 12.8B CNY (≈$1.8B) | 36 | 38 | 17 | 51 | 1 / 2 | |
| 307 | 1.2B USD | 36 | 36 | 75 | 28 | 2 / 2 | |
| 307 | 22.3B SEK (≈$2.2B) | 36 | 49 | 20 | 56 | 2 / 2 | |
| 307 | 2.2B USD | 36 | 31 | 60 | 31 | 2 / 2 | |
| 312 | 3.0B USD | 35 | 56 | 36 | 39 | 2 / 2 | |
| 312 | 1.7B USD | 35 | 43 | 34 | 35 | 2 / 2 | |
| 312 | 3.4B USD | 35 | 8 | — | 12 | 0 / 2 | |
| 312 | 2.2B USD | 35 | 8 | — | 12 | 0 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score